Laurus Labs
Market cap ₹1.11 L Cr
- P/E
- 101.77
- Day range
- ₹1,951.60 – ₹2,058.90
- 52-week range
- ₹917.95 – ₹2,089.00
- Volume
- 18.58 L
- Open
- ₹1,960.00
- Prev close
- ₹1,970.00
Latest results · Q1 FY27(consolidated)Revenue ₹2,026 Cr+29.1%Profit ₹362 Cr+123.9%Margin 17.9%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
LAURUSLABS in NSE indices and F&O
F&O margin for one lot of LAURUSLABS (850 shares)Research profile
Composite 66 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.0%
- Graham no.
- ₹216.12
- vs Graham
- -89.5%
- ROE ÷ P/B
- 0.9%
- 12-1 mom.
- +128.5%
- Return / vol
- 4.24
- Magic Formula
- #492
- Piotroski
- 5/6
- FCF yield
- 0.5%
- PEG
- 4.60
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.17 L Cr | 34.52 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.40 L Cr | 82.12 | 14.18 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.73 L Cr | 76.86 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.16 L Cr | 25.86 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.13 L Cr | 53.97 | 11.73 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| Laurus LabsLAURUSLABS | ₹1.11 L Cr | 101.77 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| CiplaCIPLA | ₹1.09 L Cr | 32.49 | 3.14 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Dr. Reddy's LabsDRREDDY | ₹1.09 L Cr | 39.03 | 2.65 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Sector median | ₹24,447 Cr | 41.53 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 14d agoHeadlines about Laurus Labs from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 102.0
- EPS (TTM)
- ₹20.23
- Price / Book
- 20.97
- ROE (FY26)
- 18.2%
- ROCE (latest year)
- 18%
- Dividend yield
- 0.10%
Moving averages (NSE)
- 20-day
- ₹2,019.69
- Price above
- 50-day
- ₹1,943.47
- Price above
- 200-day
- ₹1,422.54
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- FII
- Public
- Promoter
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the split of 29 Sept 2020: earlier bars are per pre-split share.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Expenses | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 |
| Operating Profit | 188 | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 |
| OPM % | 15% | 15% | 17% | 14% | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% |
| Other Income | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 |
| Interest | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 |
| Depreciation | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 |
| Profit before tax | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 |
| Tax % | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% |
| Net Profit | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| EPS in Rs | ₹0.69 | ₹0.43 | ₹1.40 | ₹0.23 | ₹0.37 | ₹1.71 | ₹4.33 | ₹3.02 | ₹3.61 | ₹4.66 | ₹5.17 | ₹6.80 |
From company filings, updated 27 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+16 days since Mar 2021
+51 days since Mar 2021
-29 days since Mar 2021
+97 days since Mar 2021
+15 days since Mar 2021
Strengths, risks & growth
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
Strengths
- Company has been maintaining a healthy dividend payout of 19.0%
Risks
- Stock is trading at 21.0 times its book value
- The company has delivered a poor sales growth of 7.19% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- +14%
- 5 Years
- +7%
- 3 Years
- +4%
- TTM
- +23%
Compounded Profit Growth
- 10 Years
- +21%
- 5 Years
- -2%
- 3 Years
- +4%
- TTM
- +115%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- +29%
- 3 Years
- +79%
- 1 Year
- +122%
Return on Equity
- 10 Years
- +17%
- 5 Years
- +15%
- 3 Years
- +10%
- Last Year
- +18%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 27.49% | 27.49% | 27.47% | 27.47% | 0.00 pp |
| FII | 26.52% | 25.82% | 28.00% | 30.84% | +2.84 pp |
| DII | 12.42% | 13.96% | 13.73% | 11.86% | -1.87 pp |
| Public | 33.57% | 32.73% | 30.79% | 29.85% | -0.94 pp |
Filed with NSE for Sept 2026: promoters 27.47%, public 72.53% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 8.26% (-1.89 pp)- Promoters27.5%
- Foreign institutions30.8%
- Mutual funds8.3%
- Insurance2.4%
- Other domestic institutions1.3%
- Retail12.2%
- Others17.7%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Mirae Asset Large & Midcap Fund | 1.58% | 4.10% | +0.90 pp |
| Mirae Asset ELSS Tax Saver Fund | 1.01% | 4.55% | +0.59 pp |
| Mirae Asset Midcap Fund | 0.76% | 4.31% | +0.64 pp |
| UTI Nifty200 Momentum 30 Index Fund | 0.47% | 6.54% | +1.76 pp |
| HSBC Small Cap Fund | 0.23% | 1.37% | +0.28 pp |
Scorecard
- Performance
- High
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 29.3%
- Downside volatility
- 28.1%
- Worst 5% of days
- 2.8%
- Average of that tail
- 3.9%
- Max drawdown (1Y)
- 16.3%
- Below its peak
- 4.8%
Against the market
- Beta vs Nifty 50
- 0.80
- Correlation
- 0.36
- Relative strength (3M)
- +30.9%
- ATR (14)
- 2.8%
Return
- Return 1M
- -1.8%
- Return 3M
- +25.6%
- Return 6M
- +79.7%
- Return 1Y
- +124.4%
- vs 200-day average
- +38.5%
Momentum
- RSI (14)
- 46.4
- MACD histogram
- -11.77
- Stochastic %K
- 23.5
- ADX (14)
- 19.4
- +DI / −DI
- 16.4 / 25.6
- Money flow index
- 46.5
Participation
- Delivery (20d avg)
- 48.7%
- vs its 60-day baseline
- -4.6 pts
- Volume vs 20-day
- +1.3σ
- Close vs day's VWAP
- +0.6%
- 52-week position
- 92 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹554 Cr
- FCF yield
- 0.5%
- Cash conversion
- 1.54
- Accruals ratio
- -0.054
- Net debt
- ₹2,406 Cr
- Net debt / equity
- 0.45
- EV / sales
- 12.31
- PEG
- 4.60
- Capex intensity
- 12.8%
- Revenue CAGR
- 5.3%
- Profit CAGR
- 21.2%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹1.20
Interim Dividend - Rs 1.20 Per Share
8 May 2026ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.80 Per Sh
31 Oct 2025ex-date - dividend₹0.80
Interim Dividend - Rs 0.80 Per Share
9 May 2025ex-date - dividend₹0.40
Interim Dividend - Rs 0.40 Per Share
6 Nov 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
4 Jul 2024ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.40 Per Share
8 May 2024ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.40 Per Share
2 Nov 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
7 Jul 2023ex-date - dividend₹1.20
Interim Dividend - Rs 1.20 Per Share
10 May 2023ex-date - dividend₹0.80
Interim Dividend - Rs 0.80 Per Share
3 Nov 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Jun 2022ex-date - dividend₹1.20
Interim Dividend - Rs 1.20 Per Share
10 May 2022ex-date - dividend₹0.80
Interim Dividend - Rs 0.80 Per Share
17 Nov 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
7 Jul 2021ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.80 Per Share
11 May 2021ex-date - dividend₹0.40
Interim Dividend - Rs 0.40 Per Share
8 Feb 2021ex-date - dividend₹0.80
Interim Dividend - Rs 0.80 Per Share
10 Nov 2020ex-date - splitNot available — not reported in this filing
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share
29 Sept 2020ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 1 Per Share
1 Jul 2020ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
23 Mar 2020ex-date
Company announcements
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the un-audited financial results ....
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see attached enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Please see annexed enclosure.
Filed with BSE (scrip 540222); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Sep 2026Slides
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Jan 2026TranscriptSlidesRecording
- Oct 2025TranscriptSlidesRecording
- Sep 2025Slides
Credit ratings
- Rating update · 3 Jul from care
- Rating update · 1 Jul 2025 from care
- Rating update · 20 Jun 2024 from care
- Rating update · 22 Jun 2023 from care
- Rating update · 23 Jun 2022 from care
- Rating update · 23 Mar 2021 from care
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 24 Jul 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Laurus Labs: common questions
Answered from the figures on this page.
